Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Хромогранин А в диагностике феохромоцитомы: обзор литературы
Хромогранин А в диагностике феохромоцитомы: обзор литературы
Юкина М.Ю., Давтян Д.А., Трошина Е.А., Платонова Н.М. Хромогранин А в диагностике феохромоцитомы: обзор литературы. Consilium Medicum. 2018; 20 (4): 63–67. DOI: 10.26442/2075-1753_2018.4.63-67
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Феохромоцитома – это опухоль нейроэктодермального происхождения, которая возникает из хромаффинных клеток симпатоадреналовой системы надпочечниковой или вненадпочечниковой локализации, секретирующая избыточное количество катехоламинов, протекающая с синдромом гипертензии разной степени выраженности и многообразными метаболическими расстройствами. Помимо синтеза и секреции катехоламинов эти опухоли способны вырабатывать разные биологически активные пептиды, в том числе и хромогранин А (нейроэндокринный секреторный протеин), который, наряду с другими лабораторными тестами, может помочь в диагностике феохромоцитомы.
Ключевые слова: обзор, феохромоцитома, параганглиома, хромогранин А.
Ключевые слова: обзор, феохромоцитома, параганглиома, хромогранин А.
________________________________________________
Pheochromocytoma is a tumor of neuroectodermal origin, which arises from chromaffin cells of the sympatho-adrenal system of the adrenal or extra-аdrenal localization, secreting an excessive amount of catecholamines, and accompanies with the syndrome of hypertension of varying degrees of severity and diverse metabolic disorders. In addition to the synthesis and secretion of catecholamines, these tumors are able to produce a variety of biologically active peptides, including chromogranin A (neuroendocrine secretory protein), which, along with other laboratory tests, can help in the diagnosis of pheochromocytoma.
Key words: review, pheochromocytoma, paraganglioma, chromogranin A.
Key words: review, pheochromocytoma, paraganglioma, chromogranin A.
Полный текст
Список литературы
1. Tischler AS. Molecular and cellular biology of pheochromocytomas and extra-adrenal paragangliomas. Endocr Pathol 2006; 17: 321–8.
2. Lenders JWM, Quan-Yang Duh, Eisenhofer G et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99 (6): 1915–42.
3. Eisenhofer G, Pacak K, Huynh TT et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 2011; 18 (1): 97–111.2. Lenders JWM, Quan-Yang Duh, Eisenhofer G et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99 (6): 1915–42.
4. Därr R, Lenders JWM, Hofbauer LC et al. Pheochromocytoma: Update on Disease Management. Ther Adv in Endo and Metab 2012; 3 (1): 11–26.
5. Gunawardane KPT, Grossman A. The clinical genetics of phaeochromocytomа and paraganglioma. Arch Endocrinol Metab 2017; 61 (5): 490–500.
6. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer 2014; 38 (1): 7–41.
7. Chen H, Sippel RS, O'Dorisio MS et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39: 775–83.
8. McNeil AR, Blok BH, Koelmeyer TD et al. Phaeochromocytomas discovered during coronial, autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000; 30: 648–52.
9. Mannelli M, Lenders JWM, Pacak K et al. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab 2012; 26: 507–15.
10. Omura M, Saito J, Yamaguchi K et al. Prospective study on the prevalence of secondary, hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193–202.
11. Tucker ME. Endocrine Society first to address rare adrenal-tumor care. Medscape Medical News 2014; June 5.
12. Chen Y, Xiao H, Zhou X et al. Accuracy of plasma free metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Endocr Pract 2017; Jul 13.
13. Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287 (11): 1427–34.
14. de Jong WH, Eisenhofer G, Post WJ et al. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab 2009; 94 (8): 2841–9.
15. Algeciras-Schimnich A, Preissner CM, Young WF et al. Plasma chromogranin a or urine fractionated metanephrines, follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008; 93 (1): 91–5.
16. Tasiemski A, Hammad H, Vandenbulcke F et al. Presence of chromogranin-derived antimicrobial peptides in plasma during, coronary artery bypass surgery and evidence of an immune origin of these peptides. Blood 2002; 100: 553–9.
17. Helle KB. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 2004; 79: 769–94.
18. Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965; 97: 40C–1C.
19. Lee RW, Huttner WB. Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. J Biol Chem 1983; 258: 11326–34.
20. Rosa P, Hille A, Lee RW et al. Secretogranins I and II: two tyrosine-sulfated secretory proteins common to a variety of cells secreting peptides by the regulated pathway. J Cell Biol 1985; 101: 1999–2011.
21. Guérin M, Guillemot J, Thouënnon E et al. Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma. Regul Pept 2010; 165 (1): 21–9.
22. https://www.alpco.com/chromoa-chromogranin-a-elisa
23. d'Herbomez M, Do Cao C, Vezzosi D et al. Sep, groupe des tumeurs endocrines (GTE France). Chromogranin A assay in clinical practice. Ann Endocrinol (Paris) 2010; 71 (4): 274–80.
24. Campana D, Nori F, Piscitelli L et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 967–73.
25. Adolf K, Wagner L, Bergh A et al. Secretagogin is a new neuroendocrine marker in the human prostate. Prostate 2007; 67: 472–84.
26. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore). 1991; 70 (1): 33–45.
27. d'Herbomez M, Forzy G, Bauters C et al. An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol 2007; 156 (5): 569–75.
28. Giovanella L, Ceriani L, Balerna M et al. Diagnostic value of serum chromogranin-A combined with MIBG scintigraphy inpatients with adrenal incidentalomas. Q J Nucl Med Mol Imaging 2008; 52 (1): 84–8.
29. Glinicki P, Jeske W, Bednarek-Papierska L et al. Chromogranin A (CgA) in adrenal tumours. Endokrynol Pol 2013; 64 (5): 358–62.
30. Guillemot J, Guérin M, Thouënnon E et al. Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma. PLoS One 2014; 9 (2): e88698.
31. Bílek R, Zelinka T, Vlček P et al. Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma. Physiol Res 2017; 66 (Suppl. 3): S397–S408.
32. Pregun I, Herszényi L, Juhász M et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84 (1): 22–8.
33. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37 (3): 955–64.
34. Pieroni M, Corti A, Tota B et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007; 28 (9): 1117–27.
35. Di Comite G, Rossi CM, Marinosci A et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol 2009; 85 (1): 81–7.
36. Valeur J, Milde AM, Helle KB, Berstad A. Low serum chromogranin A in patients with self-reported food hypersensitivity. Scand J Gastroenterol 2008; 43 (11): 1403–4.
37. Fossmark R, Jianu CS, Martinsen TC et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008; 43 (1): 20–4.
38. Ardill JE, O'Dorisio TM. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin North Am 2010; 39 (4): 777–90.
39. Srivastava A, Padilla O, Fischer-Colbrie R et al. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids.Am J Surg Pathol 2004; 28 (10): 1371–8.
________________________________________________
1. Tischler AS. Molecular and cellular biology of pheochromocytomas and extra-adrenal paragangliomas. Endocr Pathol 2006; 17: 321–8.
2. Lenders JWM, Quan-Yang Duh, Eisenhofer G et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99 (6): 1915–42.
3. Eisenhofer G, Pacak K, Huynh TT et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 2011; 18 (1): 97–111.
4. Därr R, Lenders JWM, Hofbauer LC et al. Pheochromocytoma: Update on Disease Management. Ther Adv in Endo and Metab 2012; 3 (1): 11–26.
5. Gunawardane KPT, Grossman A. The clinical genetics of phaeochromocytomа and paraganglioma. Arch Endocrinol Metab 2017; 61 (5): 490–500.
6. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer 2014; 38 (1): 7–41.
7. Chen H, Sippel RS, O'Dorisio MS et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39: 775–83.
8. McNeil AR, Blok BH, Koelmeyer TD et al. Phaeochromocytomas discovered during coronial, autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000; 30: 648–52.
9. Mannelli M, Lenders JWM, Pacak K et al. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab 2012; 26: 507–15.
10. Omura M, Saito J, Yamaguchi K et al. Prospective study on the prevalence of secondary, hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193–202.
11. Tucker ME. Endocrine Society first to address rare adrenal-tumor care. Medscape Medical News 2014; June 5.
12. Chen Y, Xiao H, Zhou X et al. Accuracy of plasma free metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Endocr Pract 2017; Jul 13.
13. Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287 (11): 1427–34.
14. de Jong WH, Eisenhofer G, Post WJ et al. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab 2009; 94 (8): 2841–9.
15. Algeciras-Schimnich A, Preissner CM, Young WF et al. Plasma chromogranin a or urine fractionated metanephrines, follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008; 93 (1): 91–5.
16. Tasiemski A, Hammad H, Vandenbulcke F et al. Presence of chromogranin-derived antimicrobial peptides in plasma during, coronary artery bypass surgery and evidence of an immune origin of these peptides. Blood 2002; 100: 553–9.
17. Helle KB. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 2004; 79: 769–94.
18. Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965; 97: 40C–1C.
19. Lee RW, Huttner WB. Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. J Biol Chem 1983; 258: 11326–34.
20. Rosa P, Hille A, Lee RW et al. Secretogranins I and II: two tyrosine-sulfated secretory proteins common to a variety of cells secreting peptides by the regulated pathway. J Cell Biol 1985; 101: 1999–2011.
21. Guérin M, Guillemot J, Thouënnon E et al. Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma. Regul Pept 2010; 165 (1): 21–9.
22. https://www.alpco.com/chromoa-chromogranin-a-elisa
23. d'Herbomez M, Do Cao C, Vezzosi D et al. Sep, groupe des tumeurs endocrines (GTE France). Chromogranin A assay in clinical practice. Ann Endocrinol (Paris) 2010; 71 (4): 274–80.
24. Campana D, Nori F, Piscitelli L et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 967–73.
25. Adolf K, Wagner L, Bergh A et al. Secretagogin is a new neuroendocrine marker in the human prostate. Prostate 2007; 67: 472–84.
26. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore). 1991; 70 (1): 33–45.
27. d'Herbomez M, Forzy G, Bauters C et al. An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol 2007; 156 (5): 569–75.
28. Giovanella L, Ceriani L, Balerna M et al. Diagnostic value of serum chromogranin-A combined with MIBG scintigraphy inpatients with adrenal incidentalomas. Q J Nucl Med Mol Imaging 2008; 52 (1): 84–8.
29. Glinicki P, Jeske W, Bednarek-Papierska L et al. Chromogranin A (CgA) in adrenal tumours. Endokrynol Pol 2013; 64 (5): 358–62.
30. Guillemot J, Guérin M, Thouënnon E et al. Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma. PLoS One 2014; 9 (2): e88698.
31. Bílek R, Zelinka T, Vlček P et al. Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma. Physiol Res 2017; 66 (Suppl. 3): S397–S408.
32. Pregun I, Herszényi L, Juhász M et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84 (1): 22–8.
33. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37 (3): 955–64.
34. Pieroni M, Corti A, Tota B et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007; 28 (9): 1117–27.
35. Di Comite G, Rossi CM, Marinosci A et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol 2009; 85 (1): 81–7.
36. Valeur J, Milde AM, Helle KB, Berstad A. Low serum chromogranin A in patients with self-reported food hypersensitivity. Scand J Gastroenterol 2008; 43 (11): 1403–4.
37. Fossmark R, Jianu CS, Martinsen TC et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008; 43 (1): 20–4.
38. Ardill JE, O'Dorisio TM. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin North Am 2010; 39 (4): 777–90.
39. Srivastava A, Padilla O, Fischer-Colbrie R et al. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids.Am J Surg Pathol 2004; 28 (10): 1371–8.
2. Lenders JWM, Quan-Yang Duh, Eisenhofer G et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99 (6): 1915–42.
3. Eisenhofer G, Pacak K, Huynh TT et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 2011; 18 (1): 97–111.
4. Därr R, Lenders JWM, Hofbauer LC et al. Pheochromocytoma: Update on Disease Management. Ther Adv in Endo and Metab 2012; 3 (1): 11–26.
5. Gunawardane KPT, Grossman A. The clinical genetics of phaeochromocytomа and paraganglioma. Arch Endocrinol Metab 2017; 61 (5): 490–500.
6. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer 2014; 38 (1): 7–41.
7. Chen H, Sippel RS, O'Dorisio MS et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39: 775–83.
8. McNeil AR, Blok BH, Koelmeyer TD et al. Phaeochromocytomas discovered during coronial, autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000; 30: 648–52.
9. Mannelli M, Lenders JWM, Pacak K et al. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab 2012; 26: 507–15.
10. Omura M, Saito J, Yamaguchi K et al. Prospective study on the prevalence of secondary, hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193–202.
11. Tucker ME. Endocrine Society first to address rare adrenal-tumor care. Medscape Medical News 2014; June 5.
12. Chen Y, Xiao H, Zhou X et al. Accuracy of plasma free metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Endocr Pract 2017; Jul 13.
13. Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287 (11): 1427–34.
14. de Jong WH, Eisenhofer G, Post WJ et al. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab 2009; 94 (8): 2841–9.
15. Algeciras-Schimnich A, Preissner CM, Young WF et al. Plasma chromogranin a or urine fractionated metanephrines, follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008; 93 (1): 91–5.
16. Tasiemski A, Hammad H, Vandenbulcke F et al. Presence of chromogranin-derived antimicrobial peptides in plasma during, coronary artery bypass surgery and evidence of an immune origin of these peptides. Blood 2002; 100: 553–9.
17. Helle KB. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 2004; 79: 769–94.
18. Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965; 97: 40C–1C.
19. Lee RW, Huttner WB. Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. J Biol Chem 1983; 258: 11326–34.
20. Rosa P, Hille A, Lee RW et al. Secretogranins I and II: two tyrosine-sulfated secretory proteins common to a variety of cells secreting peptides by the regulated pathway. J Cell Biol 1985; 101: 1999–2011.
21. Guérin M, Guillemot J, Thouënnon E et al. Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma. Regul Pept 2010; 165 (1): 21–9.
22. https://www.alpco.com/chromoa-chromogranin-a-elisa
23. d'Herbomez M, Do Cao C, Vezzosi D et al. Sep, groupe des tumeurs endocrines (GTE France). Chromogranin A assay in clinical practice. Ann Endocrinol (Paris) 2010; 71 (4): 274–80.
24. Campana D, Nori F, Piscitelli L et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 967–73.
25. Adolf K, Wagner L, Bergh A et al. Secretagogin is a new neuroendocrine marker in the human prostate. Prostate 2007; 67: 472–84.
26. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore). 1991; 70 (1): 33–45.
27. d'Herbomez M, Forzy G, Bauters C et al. An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol 2007; 156 (5): 569–75.
28. Giovanella L, Ceriani L, Balerna M et al. Diagnostic value of serum chromogranin-A combined with MIBG scintigraphy inpatients with adrenal incidentalomas. Q J Nucl Med Mol Imaging 2008; 52 (1): 84–8.
29. Glinicki P, Jeske W, Bednarek-Papierska L et al. Chromogranin A (CgA) in adrenal tumours. Endokrynol Pol 2013; 64 (5): 358–62.
30. Guillemot J, Guérin M, Thouënnon E et al. Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma. PLoS One 2014; 9 (2): e88698.
31. Bílek R, Zelinka T, Vlček P et al. Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma. Physiol Res 2017; 66 (Suppl. 3): S397–S408.
32. Pregun I, Herszényi L, Juhász M et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84 (1): 22–8.
33. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37 (3): 955–64.
34. Pieroni M, Corti A, Tota B et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007; 28 (9): 1117–27.
35. Di Comite G, Rossi CM, Marinosci A et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol 2009; 85 (1): 81–7.
36. Valeur J, Milde AM, Helle KB, Berstad A. Low serum chromogranin A in patients with self-reported food hypersensitivity. Scand J Gastroenterol 2008; 43 (11): 1403–4.
37. Fossmark R, Jianu CS, Martinsen TC et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008; 43 (1): 20–4.
38. Ardill JE, O'Dorisio TM. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin North Am 2010; 39 (4): 777–90.
39. Srivastava A, Padilla O, Fischer-Colbrie R et al. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids.Am J Surg Pathol 2004; 28 (10): 1371–8.
Авторы
М.Ю.Юкина*, Д.А.Давтян, Е.А.Трошина, Н.М.Платонова
*endo-yukina@yandex.ru
ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России. 117036, Россия, Москва, ул. Дмитрия Ульянова, д. 11
*endo-yukina@yandex.ru
*endo-yukina@yandex.ru
________________________________________________
M.Yu.Yukina*, D.A.Davtyan, E.A.Troshina, N.M.Platonova
National Medical Research Center of Endocrinology of the Ministry of Health of Russian Federation. 117036, Russian Federation, Moscow, ul. Dmitria Ul'ianova, d. 11*endo-yukina@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.